Michael Recht, MD, PhD, MBA
he/him/his
Professor of Clinical Pediatrics (Hematology/Oncology)Cards
About
Research
Publications
2026
Safety and real-world effectiveness of eptacog beta with emicizumab prophylaxis: an interim analysis of the ATHN 16 study
Chrisentery-Singleton T, Acharya S, Ahuja S, Amos L, Chitlur M, Daoud N, Eason A, Escobar M, Fedor C, Gupta S, Kuriakose P, Nasr S, Pennington S, Pruthi R, Recht M, Robertson A, Quon D, Wheeler A, Reding M. Safety and real-world effectiveness of eptacog beta with emicizumab prophylaxis: an interim analysis of the ATHN 16 study. Blood Vessels Thrombosis & Hemostasis 2026, 3: 100169. DOI: 10.1016/j.bvth.2026.100169.Peer-Reviewed Original ResearchEptacog betaBleeding eventsEmicizumab prophylaxisTreatment of bleeding eventsInterim analysisManagement of bleeding eventsSingle-dose effectsOpen-label studyReal-world effectivenessHemostatic medicationsThrombotic microangiopathyInitial dosePerioperative hemostasisBleeding managementHemophilia ATranexamic acidBeta doseSurgical proceduresTotal doseEmicizumabProphylaxisImmune responseBleedingAmerican ThrombosisDoseA novel transcutaneous auricular neurostimulation electrode configuration for treatment of heavy menstrual bleeding: an open-label trial
Czura C, Weyand A, Baldwin M, Recht M, Benner C, Harada K, Wade B, Luellen M, Darrow M, McWade M, Covalin A, Khodaparast N. A novel transcutaneous auricular neurostimulation electrode configuration for treatment of heavy menstrual bleeding: an open-label trial. Bioelectronic Medicine 2026, 12: 10. PMID: 41933398, PMCID: PMC13049727, DOI: 10.1186/s42234-026-00203-1.Peer-Reviewed Original ResearchPictorial blood loss assessment chartHeavy menstrual bleedingMenstrual blood lossBlood lossMenstrual bleedingVagus nerveTreatment of heavy menstrual bleedingBlood loss assessment chartHistory of heavy menstrual bleedingAuricular branchOpen-label pilot trialStudent's paired t-testOpen-label trialTrigeminal nerve branchesConsecutive menstrual cyclesDaily blood lossDuration of menstruationCervical vagus nerveTraumatic blood lossSoft tissue injuriesDevice usabilityPBAC scoreMenstrual cycleSymptom scoresThird menstruation
2025
Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B
Pipe S, Miesbach W, Recht M, Leebeek F, Key N, Castaman G, Lattimore S, Coppens M, Le Quellec S, Mahajan V, Gill S, Drelich D, Monahan P. Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B. The New England Journal Of Medicine 2025, 394: 463-474. PMID: 41358585, DOI: 10.1056/nejmoa2514332.Peer-Reviewed Original ResearchAdeno-associated virus serotype 5Factor IX expressionLead-in periodEtranacogene dezaparvovecIX expressionBleeding rateGene therapyBleeding eventsMonth 7Adverse eventsHemophilia BNeutralizing antibodiesTreatment of bleeding eventsFactor IX infusionsFactor IX prophylaxisYears of follow-upPhase 3 studySingle-dose treatmentFollow-up periodLow-grade severityOpen-labelRoutine prophylaxisMonth 6Prophylactic treatmentFollow-upSafety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study
Buckner T, Carpenter S, Daoud N, Kempton C, Lee L, Malec L, McLean T, Morton P, O'Neill C, Staber J, Wang M, Croteau S, Recht M. Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study. Haemophilia 2025, 32: 63-70. PMID: 41220279, PMCID: PMC12904170, DOI: 10.1111/hae.70151.Peer-Reviewed Original ResearchMedical record reviewProspective observational cohort studyNatural history studiesObservational cohort studyParticipant characteristicsRecord reviewAmerican ThrombosisParticipant interviewsPractice of treatmentAdverse eventsCohort studySeverity of HAMonitor useParticipantsABRATHNClinical informationHistory studiesPeopleCut-offTranscutaneous auricular neurostimulation to reduce heavy menstrual bleeding in women with and without von Willebrand disease
Czura C, Weyand A, Baldwin M, Recht M, McWade M, Covalin A, Khodaparast N. Transcutaneous auricular neurostimulation to reduce heavy menstrual bleeding in women with and without von Willebrand disease. Frontiers In Medicine 2025, 12: 1664433. PMID: 41133152, PMCID: PMC12540315, DOI: 10.3389/fmed.2025.1664433.Peer-Reviewed Original ResearchPictorial blood loss assessment chartHeavy menstrual bleedingPictorial blood loss assessment chart scoreStudent's paired t -test waMenstrual blood lossBlood lossDaily blood lossMenstrual bleedingPlatelet phenotypePreclinical modelsBlood loss assessment chartHealth-related qualityOpen-label pilot trialDaily 1-h sessionsConcomitant hormonal therapyTrigeminal nerve branchesConsecutive menstrual cyclesDuration of menstruationPilot trialVon Willebrand diseaseHealth-related quality of life scoresQuality of life scoresSoft tissue injuriesHormone therapyPBAC scoreNatural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 study
Klamroth R, Recht M, Key N, Miesbach W, Pipe S, Kaczmarek R, Drelich D, Salazar B, Le Quellec S, Monahan P, Galante N, van der Valk P, Tarrant J. Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 study. Molecular Therapy Advances 2025, 33: 101568. PMID: 40969675, PMCID: PMC12441693, DOI: 10.1016/j.omtm.2025.101568.Peer-Reviewed Original ResearchAAV serotype 5Adeno-associated virusLead-in periodNatural historyGene therapyAAV-based gene therapyLaboratory assessmentAnti-AAV5 antibodiesCorrelation of titersPhase 3 studyAssociated with older agePhase 3 trialNAb titersDetectable NAbsMedian titerHemophilia BNeutralizing antibodiesHemophilia B.Serotype 5HemophiliaImmunoglobulin MNAbsBinding antibodiesLead-InImmunoglobulin GEffectiveness of Octocog Alfa (BAY 81‐8973) to Treat People With Haemophilia A Enrolled in the ATHNdataset, Including Under‐Represented Subgroups
Chandler M, Moulton T, Charafi L, Charlet J, Recht M. Effectiveness of Octocog Alfa (BAY 81‐8973) to Treat People With Haemophilia A Enrolled in the ATHNdataset, Including Under‐Represented Subgroups. European Journal Of Haematology 2025, 115: 484-492. PMID: 40770897, PMCID: PMC12505839, DOI: 10.1111/ejh.70016.Peer-Reviewed Original ResearchThe Bleeding Disorders Research Collaborative
Valentino L, Santaella M, Witkop M, Stanhope R, Valadez S, Carlson S, Benasutti H, DiMichele D, Recht M. The Bleeding Disorders Research Collaborative. Blood Vessels Thrombosis & Hemostasis 2025, 2: 100099. PMID: 41070002, PMCID: PMC12506547, DOI: 10.1016/j.bvth.2025.100099.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCompletion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years
von Drygalski A, Gomez E, Giermasz A, Castaman G, Key N, Lattimore S, Leebeek F, Miesbach W, Recht M, Monahan P, Le Quellec S, Pipe S. Completion of phase 2b trial of etranacogene dezaparvovec gene therapy in patients with hemophilia B over 5 years. Blood Advances 2025, 9: 3543-3552. PMID: 40188458, PMCID: PMC12275190, DOI: 10.1182/bloodadvances.2024015291.Peer-Reviewed Original ResearchAdeno-associated virus serotype 5Etranacogene dezaparvovecHemophilia BRecombinant adeno-associated virus serotype 5FIX inhibitor developmentLiver-specific promoterPost-administrationSelf-administered infusionsSevere hemophilia BMulti-center trialYears post-administrationBleeding episodesOpen-labelSingle-doseSecondary endpointsIntravenous doseSingle-armGene therapyThrombotic complicationsYears post-treatmentSafety profileClinically significant elevationsAdverse eventsBleeding frequencyNeutralizing antibodiesPlain language summary of 4-year results of the GENEr8-1 clinical trial of valoctocogene roxaparvovec gene therapy for hemophilia A
Madan B, Ozelo M, Kenet G, Chou S, Dashiell-Aje E, Robinson T, Mahlangu J, Recht M, Careta F, Ruiz A, Fletcher S, Goshen D. Plain language summary of 4-year results of the GENEr8-1 clinical trial of valoctocogene roxaparvovec gene therapy for hemophilia A. Future Rare Diseases 2025, 5: 2522071. DOI: 10.1080/23995270.2025.2522071.Peer-Reviewed Original Research
Clinical Care
Overview
Michael Recht, MD, PhD, is a pediatric hematologist who focuses on treating children, adolescents, and young adults with bleeding and clotting disorders.
Dr. Recht is a professor of clinical pediatrics at Yale School of Medicine. He has been actively involved in more than 110 clinical trials, including research on gene therapy for hemophilia. Dr. Recht also serves as the chief medical and scientific officer for the National Bleeding Disorders Foundation. In this role, he helps shape the scientific direction and research strategy of the organization, working to advance the understanding and treatment of bleeding disorders. Dr. Recht received his medical and doctoral degrees from the University of Wisconsin-Madison. He completed his residency in pediatrics and fellowship in pediatric hematology-oncology at Yale New Haven Hospital.
Clinical Specialties
Pediatric Hematology & Oncology
Fact Sheets
Bleeding Disorders
Learn More on Yale Medicine
News
News
Get In Touch
Contacts
Appointment Number
Mailing Address
Pediatric Hematology & Oncology
333 Cedar Street
New Haven, CT 06510
United States
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.